Simtuzumab Explained

Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis.[1] It binds to LOXL2 and acts as an immunomodulator.[2] In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.[3]

References

  1. http://www.ama-assn.org/resources/doc/usan/simtuzumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Simtuzumab
  2. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 . WHO Drug Information . 26 . 2 . 2012 .
  3. Web site: Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis . 5 January 2016 . Gilead .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Simtuzumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.